

Amendments to the Claims:

Claims 1-37 (Cancelled)

Claim 38 (Currently Amended): A method for treating a cancer in a patient in need thereof comprising administering to said patient, concurrently or sequentially, a therapeutically effective amount of at least one indoleamine 2,3-dioxygenase (IDO) inhibitor and at least one chemotherapeutic agent, wherein said IDO inhibitor is methyl-TH-DL-trp.

Claim 39 (Currently Amended): The method of claim 38, wherein said at least one chemotherapeutic agent is selected from the group consisting of paclitaxel (Taxol®), cisplatin, docetaxel ~~docetaxel~~, carboplatin, vincristine, vinblastine, methotrexate, cyclophosphamide, CPT-11, 5-fluorouracil (5-FU), gemcitabine, estramustine, carmustine, adriamycin (doxorubicin), etoposide, arsenic trioxide, irinotecan, and epothilone derivatives.

Claim 40 (Withdrawn): The method of claim 39, wherein said at least one chemotherapeutic agent is paclitaxel.

Claim 41 (Cancelled)

Claim 42 (Cancelled)

Claim 43 (Original): The method of claim 38, wherein said at least one IDO inhibitor and said at least one chemotherapeutic agent are administered concurrently.

Claim 44 (Original): The method of claim 38, wherein said at least one IDO inhibitor and said at least one chemotherapeutic agent are administered sequentially.

Claim 45 (Original): The method of claim 44, wherein said at least one IDO inhibitor is administered before said at least one chemotherapeutic agent.

Claim 46 (Original): The method of claim 44, wherein said at least one chemotherapeutic agent is administered before said at least one IDO inhibitor.

Claim 47 (Currently Amended): The method of claim 38, wherein said cancer is selected from the group consisting of cancers of the prostate, colorectum, pancreas, cervix, stomach, endometrium, brain, liver, bladder, ovary, testis, head, neck, skin ~~(including melanoma and basal carcinoma)~~, mesothelial lining, white blood cell, ~~(including lymphoma and leukemia)~~ esophagus, breast, muscle, connective tissue, lung ~~(including small-cell lung carcinoma and non-small-cell carcinoma)~~, adrenal gland, thyroid, kidney, or bone; melanoma, basal carcinoma, lymphoma, leukemia, small-cell lung carcinoma, non-small-cell lung carcinoma, glioblastoma, mesothelioma, renal cell carcinoma, gastric carcinoma, sarcoma, choriocarcinoma, cutaneous basocellular carcinoma, and testicular seminoma.

Claims 48-54 (Cancelled)

Claim 55 (Currently Amended): The method of claim 47, wherein said cancer is selected from the group consisting of ovarian cancer, leukemia, melanoma, breast cancer, colorectal cancer, and lung cancer.

Claim 56 (Previously Presented): The method of claim 55, wherein said cancer is breast cancer.

Claim 57 (New): A method for treating a cancer in a patient in need thereof comprising administering to said patient, concurrently or sequentially, a therapeutically effective amount of at least one indoleamine 2,3-dioxygenase (IDO)

inhibitor and at least one chemotherapeutic agent, wherein said IDO inhibitor is 1-methyl-DL-tryptophan.

Claim 58 (New): The method of claim 57, wherein said at least one chemotherapeutic agent is selected from the group consisting of paclitaxel (Taxol®), cisplatin, docetaxel, carboplatin, vincristine, vinblastine, methotrexate, cyclophosphamide, CPT-11, 5-fluorouracil (5-FU), gemcitabine, estramustine, carmustine, adriamycin (doxorubicin), etoposide, arsenic trioxide, irinotecan, and epothilone derivatives.

Claim 59 (New): The method of claim 57, wherein said at least one IDO inhibitor and said at least one chemotherapeutic agent are administered concurrently.

Claim 60 (New): The method of claim 57, wherein said at least one IDO inhibitor and said at least one chemotherapeutic agent are administered sequentially.

Claim 61 (New): The method of claim 60, wherein said at least one IDO inhibitor is administered before said at least one chemotherapeutic agent.

Claim 62 (New): The method of claim 60, wherein said at least one chemotherapeutic agent is administered before said at least one IDO inhibitor.

Claim 63 (New): The method of claim 57, wherein said cancer is selected from the group consisting of cancers of the prostate, colorectum, pancreas, cervix, stomach, endometrium, brain, liver, bladder, ovary, testis, head, neck, skin, mesothelial lining, white blood cell, esophagus, breast, muscle, connective tissue, lung, adrenal gland, thyroid, kidney, or bone; melanoma, basal carcinoma, lymphoma, leukemia, small-cell lung carcinoma, non-small-cell lung carcinoma, glioblastoma, mesothelioma, renal cell carcinoma, gastric

carcinoma, sarcoma, choriocarcinoma, cutaneous basocellular carcinoma, and testicular seminoma.

Claim 64 (New): The method of claim 63, wherein said cancer is selected from the group consisting of ovarian cancer, leukemia, melanoma, breast cancer, colorectal cancer, and lung cancer.

Claim 65 (New): The method of claim 64, wherein said cancer is breast cancer.

Claim 66 (New): The method of claim 65, wherein said chemotherapeutic agent is cisplatin.